These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1359173)

  • 21. The reappearance of 10 differentiation antigens on peripheral blood lymphocytes after allogeneic bone marrow transplantation.
    Leino L; Lilius EM; Nikoskelainen J; Pelliniemi TT; Rajamäki A
    Bone Marrow Transplant; 1991 Nov; 8(5):339-44. PubMed ID: 1768967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.
    Jansen J; Hanks S; Akard LP; Thompson JM; Burns S; Chang Q; English D; Garrett P
    Bone Marrow Transplant; 1996 Mar; 17(3):377-82. PubMed ID: 8704690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation.
    Charmot D; Ragueneau M; Olive D; Maraninchi D; Mawas C
    Bone Marrow Transplant; 1987 Aug; 2(2):183-94. PubMed ID: 2901879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells.
    Jiang YZ; Kanfer EJ; Macdonald D; Cullis JO; Goldman JM; Barrett AJ
    Bone Marrow Transplant; 1991 Oct; 8(4):253-8. PubMed ID: 1756322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of recipient-specific alloreactivity: is GVHD predictable?
    Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.
    Löwenberg B; Wagemaker G; van Bekkum DW; Sizoo W; Sintnicolaas K; Hendriks WD; Hagenbeek A
    Bone Marrow Transplant; 1986 Dec; 1(2):133-40. PubMed ID: 3332128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reconstitution of the CD45RO(+) and CD20(+) lymphoid marrow population following allogeneic bone marrow transplantation for Ph(+) CML.
    Thiele J; Kvasnicka HM; Beelen DW; Welter A; Schneider S; Leder LD; Schaefer UW
    Bone Marrow Transplant; 2001 Feb; 27(4):425-31. PubMed ID: 11313672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Flow cytometric analysis of T lymphocyte subsets after human bone marrow transplantation using monoclonal antibodies and dual immunofluorescence].
    Matsue K; Yasue S; Iwabuchi K; Ohtsuka M; Ueda M; Kondo K; Shiobara S; Mori T; Matsuda T; Harada M
    Nihon Ketsueki Gakkai Zasshi; 1989 May; 52(3):659-64. PubMed ID: 2694718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical changes in sigmoid colon after allogeneic and autologous bone marrow transplantation.
    Forbes GM; Erber WN; Herrmann RP; Davies JM; Collins BJ
    J Clin Pathol; 1995 Apr; 48(4):308-13. PubMed ID: 7615847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of lymphocyte subsets in leukemia patients who received allogenic bone marrow transplantation.
    Komatsuda M
    Acta Med Okayama; 1991 Aug; 45(4):257-65. PubMed ID: 1683740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of alloreactive cytotoxic and lymphokine-secreting T lymphocytes in the development of acute graft-versus-host disease.
    Theobald M
    Transfus Sci; 1994 Sep; 15(3):189-96. PubMed ID: 10155540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune cell subset counts associated with graft-versus-host disease.
    Podgorny PJ; Liu Y; Dharmani-Khan P; Pratt LM; Jamani K; Luider J; Auer-Grzesiak I; Mansoor A; Williamson TS; Ugarte-Torres A; Hoegh-Petersen M; Stewart DA; Daly A; Khan FM; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):450-62. PubMed ID: 24406506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.